- CEO
- Chalom Sayada
- Full Time Employees
- 21
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- 72c, rue de Thionville Paris IDF France 57140
- IPO Date
- Mar 25, 1991
- Business
- ABL Diagnostics Société anonyme (ABLD.PA) is a France-based diagnostic and molecular biology company focused on the development, manufacture, and commercialization of in vitro diagnostic (IVD) assays and related software for infectious disease detection and clinical microbiology. The company provides proprietary molecular biology assays and end-to-end solutions enabling molecular detection by polymerase chain reaction (PCR) and DNA sequencing, complemented by digital and automation software platforms; its product portfolio includes real-time syndromic PCR assays, Nadis patient medical record software used in hospital networks, and clinical sample collection kits such as MediaChek. Headquartered in Woippy, France, ABL Diagnostics operates through direct sales and an international distributor network, targeting academic clinical pathology laboratories, private reference laboratories, and research institutions. The company was founded in 2000 (originating as Etablissements Fauvet Girel) and rebranded to ABL Diagnostics S.A. in 2022, subsequently listing on Euronext Paris. ABL Diagnostics is a subsidiary of Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based diagnostics group, reflecting a broader corporate structure with ongoing strategic alignment within the ABL group. The company maintains operations across France and internationally, delivering products and services to diagnostic laboratories, hospitals, and researchers through a combination of instrument-compatible assays, RUO offerings, and software-enabled data management solutions. Major business lines span molecular detection assays, sequencing-based workflows, laboratory automation integration, digital health software, and related lab infrastructure products, with a focus on HIV, hepatitis, tuberculosis, and other infectious disease areas. Ongoing strategic activities include capital market movements related to shareholding changes by the principal shareholder, ABL S.A., and continued expansion of product lines, partnerships, and geographic coverage to support diagnostic workflows in both routine clinical laboratories and research settings.